#Patient Identifier	HCV	HBV	EtOH	NASH	Pathologic Vascular Invasion	Time to unresectable or metastatic disease in months	Extrahepatic Disease	Prior Local Therapy	Type of Prior Local Therapy	Child pugh classification grade	Systemic Treatment	Best objective response rate	Diagnosis Age	Metastasis	Metastasis bone	Prior Surgical Resection	First Line Therapy	Overall Survival from Advanced Disease	Overall Survival Months Reported by DMT	Cohort	Detailed Primary Site	Disease Free (Months)	Smoking History	Person Cigarette Smoking History Pack Year Value	Tobacco Type	Alcohol History Documented	Alcohol Consumption Frequency	Initial Treatment	Prior Treatment to IMPACT Sample	HPV Status	Disease Free Status	Disease Extent At Time IMPACT Was Sent	Patient's Vital Status	WHO Class	Histology	Immunosuppression	Clinical Trial	AGENT	Comments	Sex Reported by DMT	Overall Status Reported by DMT	Neoplasm Histologic Type Name	Metastasis liver	Metastasis lung	Metastasis peritoneum	Time to Recurrence (months)	PED Age	PED Sex	Pediatric Sample	Treatment	Primary Tumor Localization Type	Primary histology	Initial Stage	Staging System	Recurrence	Adjuvant Treatment	Number of Prior Therapies	Primary Radiation Therapy	BRAIN METS	Performance Status	Relapse	Vascular invasion indicator	Turin	Radioactive Iodine	RAI Uptake	Tumor Site	Prior Thyroid Cancer	Radiation History	Family History Cancer Type	Family History of Thyroid Cancer	Year of Diagnosis	Pathology Cancer Maximum Dimension (cm)	Anaplastic Percentage	KI 67	PAX8	American Joint Committee on Cancer Tumor Stage Code	Neoplasm Disease Lymph Node Stage American Joint Committee on Cancer Code	M Stage	Disease Surgical Margin Status	Lymph Node(s) Examined Number	Largest Size	Lymphomatous Extranodal Site Involvement Indicator	Chemotherapy Details	Pre-IMPACT TKI	Target Therapy	Response to Target Therapy	Immunotherapy	Chemotherapy	Neuroendocrine carcinoma	Msk visits	Treatment at msk	Treated or untreated at time of initial visit	Blood collection	MSK Department	Smoker	Colonoscopy	Esophagogastroduodenoscopy	PET Scan	CT Cap	Bronchoscopy	Age At Initial Pathological Diagnosis	ECOG status	Paraneoplastic syndrome	Surgery	Surgery Procedure	Best response to everolimus	Best response to Sunitinib	Best response to platinum	Best response to alkylating agent (temozolomide or dacarbazine)	PRRT Therapy	Enrollment on clinical trial based on IMPACT	TIme to first recurrence (months)	First Recurrence Resectable for NED	Did patient start adjuvant postoperative radiotherapy?	CRDB_ADJ_TXT	CRDB_NOSYSTXT	CRDB_PRIOR_RX	CRDB_BRAINMET	CRDB_ECOG	Other Patient ID	12-245 Part A Consented	12-245 Part C Consented	Primary melanoma tumor ulceration	RAF Inhibitor	IMPACT Pre RAFi	KIT Inhibitor	KIT inhibitor type	IMPACT Pre KITi	PSAT IMPACT order	Radiation Therapy	IMPACT directed SOC Treatment	Adjuvant Postoperative Targeted Therapy Administered Indicator	Cytotoxic Treatment	BMI	Protocol Number	Patient Current Age	Race Category	Religion	Sex	Ethnicity Category	Overall Survival Status	Overall Survival (Months)	Pediatric Case Indicator	Protocol	Diabetes Status	Insulin Status	HTN Status	HL status	Surgery At MSKCC	Adjuvant Chemotherapy	Treatment best response	Concurrent Treatment	Hormone Therapy	Stage	Tumor Other Histologic Subtype	Performance status	Neoplasm American Joint Committee on Cancer Clinical Primary Tumor T Stage	Neoplasm American Joint Committee on Cancer Clinical Regional Lymph Node N Stage	Treatment Response	Prior History of Ulcerative Colitis	History of Crohn Disease	Insulin Use	Lynch Syndrome	Stage at Testing	Resection of the primary	Resection at MSKCC	Cytoreductive Surgery	Time to Surgery	R0 Surgery	Pre-operative Chemotherapy	Adjuvant Chemotherapy	Treatment for MTS Disease Before MTS Sampling	Type of Treatment Before Sampling	Time to Metastasis (months)	Neoadjuvant   Systemic Chemotherapy	Year of rc	Recurrence Status Interval Years	Vital Status Interval Years	Resection of Mets	Time To Death (Months)	Did patient start neoadjuvant preoperative radiotherapy?	Neoadj Systemic Treatment Before First Surgery	Preop RT before first surgery	Adjuvant therapy after first surgery?	Adjuvant RT after first surgery?	Prior fluoropyrimidine (before sample collected for sequencing)	Prior oxaliplatin (before sample collected for sequencing)	Prior irinotecan (before sample collected for sequencing)	Prior anti-EGFR (before sample collected for sequencing)	Prior anti-VEGF (before sample collected for sequencing)	Prior HAI (before sample collected for sequencing)	Prior IP (before sample collected for sequencing)	Prior RT (of sequenced site)	Multiple Breast Primaries	Multiple Breast Primaries Sequenced	Primary Tumor Laterality	Side Surgery	Recurrence at Diagnosis	Distant Recurrence	Time from Diagnosis to IMPACT in months	ER Metastatic Status	PR Metastatic Status	HER2 Metastatic Status	Known Molecular Classifier	ER Primary Status	PR Primary Status	HER2 Primary Status	Menopasue status at Diagnosis	N Stage	Nuclear Grade	Age at BMI Measurement	Height (metres)	Patient Weight	BMI Category	Hypertension diagnosis	Hypercholesterolemia	Statin Used	Metformin Used	NSAID Used	F-Uptime (months)	Stopped Smoking Year	Initial LN Status	Biopsy From Irradiated Site	Platinum Doublet	Sarcomatoid features	Histopathology	Patient Smoking History Category	Localized or Metastaic at Diagnosis	Patient received Radiation or Chemotherapy	Interval to Mets	Months to Local Recurrence.	CRDB_CONSENT_DATE_DAYS	CRDB_SURVIVAL_STATUS	CRDB_TREATMENT_END_DAYS	CRDB_OFF_STUDY_DAYS	CRDB_BASIC_COMMENTS	Family History of Cancer	Head VS Body/Tail Primary Pancreas	Time to diagnosis with advanced disease	Sample procurred pre chemotherapy	Patient Height	CA-125	Lymph Nodes	Hysterectomy at MSK	Other History	Risk Group	Neoplasm American Joint Committee on Cancer Clinical Distant Metastasis M Stage	Lvi	Chemotherapy Response	Salvage Chemo	Igcccg stage
#Identifier to uniquely specify a patient.	HCV	HBV	EtOH	NASH	Pathologic Vascular Invasion	Time to unresectable or metastatic disease in months	Extrahepatic Disease	Prior Local Therapy	Type of Prior Local Therapy	Child pugh classification grade	Systemic Treatment	Best objective response rate	Age at which a condition or disease was first diagnosed.	Metastasis.	Metastasis bone	Prior Surgical Resection	First Line Therapy	Overall Survival from Advanced Disease	Overall Survival Months Reported by DMT	Cohort.	Detailed Primary Site	Disease free (months) since initial treatment.	Smoking History	Numeric computed value to represent lifetime tobacco exposure defined as number of cigarettes smoked per day x number of years smoked divided by 20.	Tobacco Type	Alcohol History Documented	Alcohol Consumption Frequency	Initial Treatment	Prior Treatment to IMPACT Sample	HPV status.	Disease free status since initial treatment.	Disease Extent At Time IMPACT Was Sent	The survival state of the person.	WHO class.	Histology	Suppression of the immune system.	Clinical Trial	AGENT	Comments.	Sex Reported by DMT	Overall Status reported by DMT	Text term for the structural pattern of cancer cells used to define a microscopic diagnosis.	Metastasis liver	Metastasis lung	Metastasis peritoneum	Time to Recurrence (months)	PED Age	PED Sex	Pediatric Sample	Treatment	Primary Tumor Localization Type	Primary Histology	Initial Stage	Staging System.	Recurrence	Adjuvant treatment.	Number of Prior Therapies	Primary radiation therapy.	Brain Metatstasis	The functional level of the patient based on the Zubrod performance scale.	Relapse.	Vascular invasion indicator	Turin	Radioactive Iodine	RAI Uptake	Tumor Site	Prior Thyroid Cancer	History of radiation	Family history cancer type.	Family History of Thyroid Cancer	Year of Diagnosis	Pathology cancer maximum dimension (cm).	Anaplastic Percentage	KI 67	PAX8	Code of pathological T (primary tumor) to define the size or contiguous extension of the primary tumor (T), using staging criteria from the American Joint Committee on Cancer (AJCC).	The codes that represent the stage of cancer based on the nodes present (N stage) according to criteria based on multiple editions of the AJCC's Cancer Staging Manual.	M Stage	Text descriptor of the conclusive results following examination of tissue margin(s) for the presence of disease.	The total number of lymph nodes removed and pathologically assessed for disease.	Largest Size	Indicator that identifies whether a patient with malignant lymphoma has lymphomatous involvement of an extranodal site.	Chemotherapy details	Pre-IMPACT TKI	Did the patient recieve target therapy	Did the patient respond to Target Therapy	Immunotherapy	Chemotherapy.	Neuroendocrine carcinoma	Msk visits	Treatment at msk	Treated or untreated at time of initial visit	Blood collection	MSK Department	Indicates if person is a smoker.	Colonoscopy	Esophagogastroduodenoscopy	PET Scan	CT Cap	Bronchoscopy	Age At Initial Pathological Diagnosis	ECOG status	Paraneoplastic syndrome	Surgery.	Surgery Procedure	Best response to everolimus	Best response to Sunitinib	Best response to platinum	Best response to alkylating agent (temozolomide or dacarbazine)	Peptide Receptor Radionuclide Therapy (PRRT)	Enrollment on clinical trial based on IMPACT	TIme to first recurrence (months)	First Recurrence Resectable for NED	A yes/no indicator that asks whether the patient started adjuvant postoperative radiotherapy.	Has the patient received adjuvant systemic therapy?	What is the number of prior systemic therapies (Inclusion of endocrine, cytotoxic, biologic therapies)?	Has the patient received prior radiotherapy?	Does the patient have brain metastases?	What is the patient's ECOG status?	Legacy DMP patient identifier (DMPnnnn)	12-245 Part A Consented Status	12-245 Part C Consented	Melanoma ulceration indicator	RAF Inhibitor	IMPACT Pre RAFi	KIT Inhibitor	KIT inhibitor type	IMPACT Pre KITi	PSAT IMPACT order	Radiation Therapy.	IMPACT directed SOC Treatment	Text term to signify postoperative adjuvant cancer therapies which use drugs to act upon specific molecules, metabolic pathways or processes involved in carcinogenesis, tumor growth, or tumor spread. [Manually-curated]	Cytotoxic Treatment	Body Mass Index	Protocol Number	Patient Current Age	The text for reporting information about race.	Religion	Sex	The text for reporting information about ethnicity.	Overall patient survival status.	Overall survival in months since initial diagonosis.	Indication on whether this case is a pediatric patient or not	Protocol.	Diabetes Status	Insulin Status	HTN Status	Hl Status	Surgery At MSKCC	Adjuvant Chemotherapy	Treatment best response	Concurrent Treatment	Hormone therapy.	Stage	Text to describe a tumor's histologic subtype or mixed diagnosis that is different from previously specified options.	Performance status	Extent of the primary cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.	Extent of the regional lymph node involvement for the cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.	Treatment Response	Prior History of Ulcerative Colitis	History of Crohn Disease	Insulin use description	Lynch Syndrome	Stage at Testing	Resection of the primary	Resection at MSKCC yes/no indicator	Cytoreductive Surgery	Time till surgery description	R0 Surgery description	Pre-operative Chemotherapy description	Adjuvant chemotherapy receivec	Treatment for MTS Disease Before MTS Sampling	Type of Treatment Before Sampling	Time to metastasis (months).	Neoadjuvant   Systemic Chemotherapy	Year of rc	Recurrence Status Interval Years	Vital Status Interval Years	Resection of Mets	Time To Death (Months)	A yes/no indicator that asks whether the patient startedneoadjuvant preoperative radiotherapy?	Neoadj Systemic Treatment Before First Surgery	Preop RT before first surgery	Adjuvant therapy after first surgery?	Adjuvant RT after first surgery?	Prior fluoropyrimidine (before sample collected for sequencing)	Prior oxaliplatin (before sample collected for sequencing)	Prior irinotecan (before sample collected for sequencing)	Prior anti-EGFR (before sample collected for sequencing)	Prior anti-VEGF (before sample collected for sequencing)	Prior HAI (before sample collected for sequencing)	Prior IP (before sample collected for sequencing)	Prior RT (of sequenced site)	Multiple Breast Primaries	Multiple Breast Primaries Sequenced	For tumors in paired organs, designates the side on which the cancer originates.	Side Surgery	Recurrence at Diagnosis	Distant recurrence.	Time from Diagnosis to IMPACT in months	ER Metastatic Status	PR Metastatic Status	HER2 Metastatic Status	Known Molecular Classifier	ER Primary Status	PR Primary Status	HER2 Primary Status	Menopasue status at Diagnosis	N Stage	Nuclear Grade	Age at BMI Measurement	Height (metres)	Weight measured in kilograms.	BMI Category	Hypertension diagnosis	Hypercholesterolemia	Statin Used	Metformin Used	NSAID Used	F-Uptime in months.	The year in which the participant quit smoking.	Initial LN Status	Biopsy From Irradiated Site	Platinum Doublet	Presence of sarcomatoid features	Histopathology	Category describing current smoking status and smoking history as self-reported by a patient.	Localized or Metastaic at Diagnosis	Patient received Radiation or Chemotherapy	Interval to Mets	Months to local recurrence.	12-245 consent date.	The patient's survival status.	The patient's 12-245 treatment end date.	The patient's 12-245 off study date.	The basic comments at enrollment for 12-245.	Family history of cancer.	Head VS Body/Tail Primary Pancreas	Time to diagnosis with advanced disease	Sample procurred pre chemotherapy	Height in centimeters.	CA-125	Lymph Nodes	Yes or No value if Hysterectomy was performed at MSK	Other History	Risk group.	Extent of the distant metastasis for the cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.	Lvi	Chemotherapy response	Salvage Chemo	Igcccg stage
#STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	NUMBER	NUMBER	STRING	STRING	NUMBER	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	NUMBER	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	NUMBER	NUMBER	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	NUMBER	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING
#0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PATIENT_ID	HCV	HBV	ETOH	NASH	PATHOLOGIC_VASCULAR_INVASION	TIME_TO_UNRESECTABLE_OR_METASTATIC_DISEASE_MONTHS	EXTRAHEPATIC_DISEASE	PRIOR_LOCAL_THERAPY	TYPE_OF_PRIOR_LOCAL_THERAPY	CHILD_PUGH_CLASSIFICATION	SYSTEMIC_TREATMENT	BEST_ORR	AGE	METASTASIS	METASTASIS_BONE	PRIOR_SURGICAL_RESECTION	FIRST_LINE_THERAPY	OS_MONTHS_ADVANCED_DISEASE	OS_MONTHS_DMT	COHORT	DETAILED_PRIMARY_SITE	DFS_MONTHS	SMOKING_HISTORY	SMOKING_PACK_YEARS	TOBACCO_TYPE	ALCOHOL_HISTORY_DOCUMENTED	ALCOHOL_CONSUMPTION_FREQUENCY	INITIAL_TREATMENT	PRIOR_TX_TO_IMPACT_SAMPLE	HPV_STATUS	DFS_STATUS	DISEASE_EXTENT	VITAL_STATUS	WHO_CLASS	HISTOLOGY	IMMUNOSUPPRESSION	CLINICAL_TRIAL	AGENT	COMMENTS	SEX_DMT	OS_STATUS_DMT	HISTOLOGICAL_DIAGNOSIS	METASTASIS_LIVER	METASTASIS_LUNG	METASTASIS_PERITONEUM	TIME_TO_RECURRENCE_MONTHS	PED_AGE	PED_SEX	PEDIATRIC_SAMPLE	TREATMENT	PRIMARY_TUMOR_LOCALIZATION_TYPE	PRIMARY_HISTOLOGY	INITIAL_STAGE	STAGING_SYSTEM	RECURRENCE	ADJUVANT_TX	NUM_PRIOR_THERAPIES	PRIMARY_RADIATION_THERAPY	BRAIN_METS	ECOG_SCORE	RELAPSE	VASCULAR_INVASION_INDICATOR	TURIN	RAI	RAI_UPTAKE	TUMOR_SITE	PRIOR_THYROID_CANCER	RADIATION_HISTORY	FAMILY_HISTORY_CANCER_TYPE	FAMILY_HISTORY_OF_THYROID_CANCER	YEAR_OF_DIAGNOSIS	PATH_CANCER_MAX_DIM_CM	ANAPLASTIC_PERCENTAGE	KI_67	PAX8	PATH_T_STAGE	PATH_N_STAGE	M_STAGE	PATH_MARGIN	LYMPH_NODE_EXAMINED_COUNT	LARGEST_SIZE	EXTRANODAL_INVOLVEMENT	CHEMO_DETAILS	IMPACT_PRE_TKI	TARGET_THERAPY	RESPONSE_TO_TARGET_THERAPY	IMMUNE_TREATMENT	CHEMOTHERAPY	NEUROENDOCRINE_CARCINOMA	MSK_VISITS	TREATMENT_AT_MSK	TREATED_OR_UNTREATED_AT_TIME_OF_INITIAL_VISIT	BLOOD_COLLECTION	MSK_DEPT	SMOKER	COLONOSCOPY	EGD	PET_SCAN	CT_CAP	BRONCHOSCOPY	AGE_AT_INITIAL_PATHOLOGIC_DIAGNOSIS	ECOG_STATUS	PARANEOPLASTIC_SYNDROME	SURGERY	SURGERY_PROCEDURE	BEST_RESPONSE_TO_EVEROLIMUS	BEST_RESPONSE_TO_SUNITINIB	BEST_RESPONSE_TO_PLATINUM	BEST_RESPONSE_TO_ALKYLATING_AGENT	PRRT_THERAPY	ENROLLMENT_ON_CLINICAL_TRIAL_BASED_ON_IMPACT	TIME_TO_FIRST_RECURRENCE	FIRST_RECURRENCE_RESECTABLE_FOR_NED	RADIATION_TREATMENT_ADJUVANT	CRDB_ADJ_TXT	CRDB_NOSYSTXT	CRDB_PRIOR_RX	CRDB_BRAINMET	CRDB_ECOG	OTHER_PATIENT_ID	PARTA_CONSENTED_12_245	PARTC_CONSENTED_12_245	PRIMARY_MELANOMA_TUMOR_ULCERATION	RAF_INHIBITOR	IMPACT_PRE_RAFI	KIT_INHIBITOR	KITI_AGENT	IMPACT_PRE_KITI	PSAT_IMPACT_ORDER	RADIATION_THERAPY	IMPACT_DIRECTED_SOC_TX	TARGETED_MOLECULAR_THERAPY	CYTOTOXIC_TREATMENT	BMI	PROTOCOL_NUM	AGE_CURRENT	RACE	RELIGION	SEX	ETHNICITY	OS_STATUS	OS_MONTHS	PED_IND	PROTOCOL	DIABETES_STATUS	INSULIN_STATUS	HTN_STATUS	HL_STATUS	SURGERY_AT_MSKCC	ADJUVANT_CHEMO	TREATMENT_BEST_RESPONSE	CONCURRENT_TREATMENT	TREATMENT_HORMONE_THERAPY	STAGE	HISTOLOGICAL_SUBTYPE	PERFORMANCE_STATUS	CLIN_T_STAGE	CLIN_N_STAGE	TREATMENT_RESPONSE	HISTORY_OF_ULCERATIVE_COLITIS	HISTORY_OF_CROHNS_DISEASE	INSULIN_USE	LYNCH_SYNDROME	STAGE_AT_TESTING	PRIMARY_RESECTION	RESECTION_AT_MSKC	CYTOREDUCTIVE_SURGERY	TIME_TO_SURGERY	R0_SURGERY	PREOP_CT	ADJUVANT_CT	TREATMENT_FOR_MTS_DISEASE_BEFORE_MTS_SAMPLING	TYPE_OF_TREATMENT_BEFORE_SAMPLING	TIME_TO_MET_MONTHS	NEOADJUVANT_SYSTEMIC_CHEMO	YEAR_OF_RC	RECURRENCE_STATUS_INTERVAL_YEARS	VITAL_STATUS_INTERVAL_YEARS	METASTATIC_RESECTION	TIME_TO_DEATH_MONTHS	RADIATION_TREATMENT_NEOADJUVANT	NEOADJ_TX_BEFORE_FIRST_SURGERY	PREOP_RT_BEFORE_FIRST_SURGERY	ADJ_TX_AFTER_FIRST_SURGERY	ADJ_RT_AFTER_FIRST_SURGERY	PRIOR_FLUOROPYRIMIDINE	PRIOR_OXALIPLATIN	PRIOR_IRINOTECAN	PRIOR_ANTI_EGFR	PRIOR_ANTI_VEGF	PRIOR_HAI	PRIOR_IP	PRIOR_RT_OF_SEQUENCED_SITE	MULTIPLE_BREAST_PRIMARIES	MULTIPLE_BREAST_PRIMARIES_SEQUENCE	LATERALITY	SIDE_SURGERY	RECURRENCE_AT_DIAGNOSIS	DISTANT_RECURRENCE	DX_TO_IMPACT_EXTENT_MONTHS	ER_STATUS_METASTASIS	PR_STATUS_METASTASIS	HER2_STATUS_METASTASIS	KNOWN_MOLECULAR_CLASSIFIER	ER_STATUS_PRIMARY	PR_STATUS_PRIMARY	HER2_STATUS_PRIMARY	MENOPAUSE_STATUS_AT_DIAGNOSIS	N_STAGE	NUCLEAR_GRADE	AGE_AT_BMI_MEASUREMENT	HEIGHT_M	WEIGHT	BMI_CATEGORY	HYPERTENSION_DIAGNOSIS	HYPERCHOLESTEROLEMIA	STATIN_USE	METFORMIN_USE	NSAID_USE	FUPTIME_MONTHS	SMOKING_YEAR_STOPPED	INITIAL_LN_STATUS	BIOPSY_FROM_IRRADIATED_SITE	PLATINUM_DOUBLET	SARCOMATOID_FEATURES	HISTOPATHOLOGY	TOBACCO_SMOKING_HISTORY_INDICATOR	LOCALIZED_VS_METS_AT_DX	RADIATION_OR_CHEMOTHERAPY	INTERVAL_TO_METS	MONTHS_TO_LOCAL_RECURRENCE	CRDB_CONSENT_DATE_DAYS	CRDB_SURVIVAL_STATUS	CRDB_TREATMENT_END_DAYS	CRDB_OFF_STUDY_DAYS	CRDB_BASIC_COMMENTS	FAMILY_HISTORY_OF_CANCER	HEAD_VS_BODY_TAIL_PRIMARY_PANCREAS	TIME_TO_DIAGNOSIS_WITH_ADVANCED_DISEASE	SAMPLE_PRE_CHEMO	HEIGHT	CA_125	LYMPH_NODES	HYSTERECTOMY_AT_MSK	HISTORY_OTHER	RISK_GROUP	CLIN_M_STAGE	LVI	CHEMOTHERAPY_RESPONSE	SALVAGE_CHEMO	IGCCCG_STAGE
P-0003533													20						6.3			14.5									Recurred/Progressed		AWD																																						2014					Tx												Yes																											NO	1	NO	NO	1	N/A		NO														22	White	CATHOLIC/ROMAN	Male	Non-Spanish; non-Hispanic	DECEASED	25.216	No															N1																																																														6												7363	Dead	7981	NA	NA										poor	M0		Resistant	No	
#Patient Identifier	HCV	HBV	EtOH	NASH	Pathologic Vascular Invasion	Time to unresectable or metastatic disease in months	Extrahepatic Disease	Prior Local Therapy	Type of Prior Local Therapy	Child pugh classification grade	Systemic Treatment	Best objective response rate	Diagnosis Age	Metastasis	Metastasis bone	Prior Surgical Resection	First Line Therapy	Overall Survival from Advanced Disease	Overall Survival Months Reported by DMT	Cohort	Detailed Primary Site	Disease Free (Months)	Smoking History	Person Cigarette Smoking History Pack Year Value	Tobacco Type	Alcohol History Documented	Alcohol Consumption Frequency	Initial Treatment	Prior Treatment to IMPACT Sample	HPV Status	Disease Free Status	Disease Extent At Time IMPACT Was Sent	Patient's Vital Status	WHO Class	Histology	Immunosuppression	Clinical Trial	AGENT	Comments	Sex Reported by DMT	Overall Status Reported by DMT	Neoplasm Histologic Type Name	Metastasis liver	Metastasis lung	Metastasis peritoneum	Time to Recurrence (months)	PED Age	PED Sex	Pediatric Sample	Treatment	Primary Tumor Localization Type	Primary histology	Initial Stage	Staging System	Recurrence	Adjuvant Treatment	Number of Prior Therapies	Primary Radiation Therapy	BRAIN METS	Performance Status	Relapse	Vascular invasion indicator	Turin	Radioactive Iodine	RAI Uptake	Tumor Site	Prior Thyroid Cancer	Radiation History	Family History Cancer Type	Family History of Thyroid Cancer	Year of Diagnosis	Pathology Cancer Maximum Dimension (cm)	Anaplastic Percentage	KI 67	PAX8	American Joint Committee on Cancer Tumor Stage Code	Neoplasm Disease Lymph Node Stage American Joint Committee on Cancer Code	M Stage	Disease Surgical Margin Status	Lymph Node(s) Examined Number	Largest Size	Lymphomatous Extranodal Site Involvement Indicator	Chemotherapy Details	Pre-IMPACT TKI	Target Therapy	Response to Target Therapy	Immunotherapy	Chemotherapy	Neuroendocrine carcinoma	Msk visits	Treatment at msk	Treated or untreated at time of initial visit	Blood collection	MSK Department	Smoker	Colonoscopy	Esophagogastroduodenoscopy	PET Scan	CT Cap	Bronchoscopy	Age At Initial Pathological Diagnosis	ECOG status	Paraneoplastic syndrome	Surgery	Surgery Procedure	Best response to everolimus	Best response to Sunitinib	Best response to platinum	Best response to alkylating agent (temozolomide or dacarbazine)	PRRT Therapy	Enrollment on clinical trial based on IMPACT	TIme to first recurrence (months)	First Recurrence Resectable for NED	Did patient start adjuvant postoperative radiotherapy?	CRDB_ADJ_TXT	CRDB_NOSYSTXT	CRDB_PRIOR_RX	CRDB_BRAINMET	CRDB_ECOG	Other Patient ID	12-245 Part A Consented	12-245 Part C Consented	Primary melanoma tumor ulceration	RAF Inhibitor	IMPACT Pre RAFi	KIT Inhibitor	KIT inhibitor type	IMPACT Pre KITi	PSAT IMPACT order	Radiation Therapy	IMPACT directed SOC Treatment	Adjuvant Postoperative Targeted Therapy Administered Indicator	Cytotoxic Treatment	BMI	Protocol Number	Patient Current Age	Race Category	Religion	Sex	Ethnicity Category	Overall Survival Status	Overall Survival (Months)	Pediatric Case Indicator	Protocol	Diabetes Status	Insulin Status	HTN Status	HL status	Surgery At MSKCC	Adjuvant Chemotherapy	Treatment best response	Concurrent Treatment	Hormone Therapy	Stage	Tumor Other Histologic Subtype	Performance status	Neoplasm American Joint Committee on Cancer Clinical Primary Tumor T Stage	Neoplasm American Joint Committee on Cancer Clinical Regional Lymph Node N Stage	Treatment Response	Prior History of Ulcerative Colitis	History of Crohn Disease	Insulin Use	Lynch Syndrome	Stage at Testing	Resection of the primary	Resection at MSKCC	Cytoreductive Surgery	Time to Surgery	R0 Surgery	Pre-operative Chemotherapy	Adjuvant Chemotherapy	Treatment for MTS Disease Before MTS Sampling	Type of Treatment Before Sampling	Time to Metastasis (months)	Neoadjuvant   Systemic Chemotherapy	Year of rc	Recurrence Status Interval Years	Vital Status Interval Years	Resection of Mets	Time To Death (Months)	Did patient start neoadjuvant preoperative radiotherapy?	Neoadj Systemic Treatment Before First Surgery	Preop RT before first surgery	Adjuvant therapy after first surgery?	Adjuvant RT after first surgery?	Prior fluoropyrimidine (before sample collected for sequencing)	Prior oxaliplatin (before sample collected for sequencing)	Prior irinotecan (before sample collected for sequencing)	Prior anti-EGFR (before sample collected for sequencing)	Prior anti-VEGF (before sample collected for sequencing)	Prior HAI (before sample collected for sequencing)	Prior IP (before sample collected for sequencing)	Prior RT (of sequenced site)	Multiple Breast Primaries	Multiple Breast Primaries Sequenced	Primary Tumor Laterality	Side Surgery	Recurrence at Diagnosis	Distant Recurrence	Time from Diagnosis to IMPACT in months	ER Metastatic Status	PR Metastatic Status	HER2 Metastatic Status	Known Molecular Classifier	ER Primary Status	PR Primary Status	HER2 Primary Status	Menopasue status at Diagnosis	N Stage	Nuclear Grade	Age at BMI Measurement	Height (metres)	Patient Weight	BMI Category	Hypertension diagnosis	Hypercholesterolemia	Statin Used	Metformin Used	NSAID Used	F-Uptime (months)	Stopped Smoking Year	Initial LN Status	Biopsy From Irradiated Site	Platinum Doublet	Sarcomatoid features	Histopathology	Patient Smoking History Category	Localized or Metastaic at Diagnosis	Patient received Radiation or Chemotherapy	Interval to Mets	Months to Local Recurrence.	CRDB_CONSENT_DATE_DAYS	CRDB_SURVIVAL_STATUS	CRDB_TREATMENT_END_DAYS	CRDB_OFF_STUDY_DAYS	CRDB_BASIC_COMMENTS	Family History of Cancer	Head VS Body/Tail Primary Pancreas	Time to diagnosis with advanced disease	Sample procurred pre chemotherapy	Patient Height	CA-125	Lymph Nodes	Hysterectomy at MSK	Other History	Risk Group	Neoplasm American Joint Committee on Cancer Clinical Distant Metastasis M Stage	Lvi	Chemotherapy Response	Salvage Chemo	Igcccg stage
#Identifier to uniquely specify a patient.	HCV	HBV	EtOH	NASH	Pathologic Vascular Invasion	Time to unresectable or metastatic disease in months	Extrahepatic Disease	Prior Local Therapy	Type of Prior Local Therapy	Child pugh classification grade	Systemic Treatment	Best objective response rate	Age at which a condition or disease was first diagnosed.	Metastasis.	Metastasis bone	Prior Surgical Resection	First Line Therapy	Overall Survival from Advanced Disease	Overall Survival Months Reported by DMT	Cohort.	Detailed Primary Site	Disease free (months) since initial treatment.	Smoking History	Numeric computed value to represent lifetime tobacco exposure defined as number of cigarettes smoked per day x number of years smoked divided by 20.	Tobacco Type	Alcohol History Documented	Alcohol Consumption Frequency	Initial Treatment	Prior Treatment to IMPACT Sample	HPV status.	Disease free status since initial treatment.	Disease Extent At Time IMPACT Was Sent	The survival state of the person.	WHO class.	Histology	Suppression of the immune system.	Clinical Trial	AGENT	Comments.	Sex Reported by DMT	Overall Status reported by DMT	Text term for the structural pattern of cancer cells used to define a microscopic diagnosis.	Metastasis liver	Metastasis lung	Metastasis peritoneum	Time to Recurrence (months)	PED Age	PED Sex	Pediatric Sample	Treatment	Primary Tumor Localization Type	Primary Histology	Initial Stage	Staging System.	Recurrence	Adjuvant treatment.	Number of Prior Therapies	Primary radiation therapy.	Brain Metatstasis	The functional level of the patient based on the Zubrod performance scale.	Relapse.	Vascular invasion indicator	Turin	Radioactive Iodine	RAI Uptake	Tumor Site	Prior Thyroid Cancer	History of radiation	Family history cancer type.	Family History of Thyroid Cancer	Year of Diagnosis	Pathology cancer maximum dimension (cm).	Anaplastic Percentage	KI 67	PAX8	Code of pathological T (primary tumor) to define the size or contiguous extension of the primary tumor (T), using staging criteria from the American Joint Committee on Cancer (AJCC).	The codes that represent the stage of cancer based on the nodes present (N stage) according to criteria based on multiple editions of the AJCC's Cancer Staging Manual.	M Stage	Text descriptor of the conclusive results following examination of tissue margin(s) for the presence of disease.	The total number of lymph nodes removed and pathologically assessed for disease.	Largest Size	Indicator that identifies whether a patient with malignant lymphoma has lymphomatous involvement of an extranodal site.	Chemotherapy details	Pre-IMPACT TKI	Did the patient recieve target therapy	Did the patient respond to Target Therapy	Immunotherapy	Chemotherapy.	Neuroendocrine carcinoma	Msk visits	Treatment at msk	Treated or untreated at time of initial visit	Blood collection	MSK Department	Indicates if person is a smoker.	Colonoscopy	Esophagogastroduodenoscopy	PET Scan	CT Cap	Bronchoscopy	Age At Initial Pathological Diagnosis	ECOG status	Paraneoplastic syndrome	Surgery.	Surgery Procedure	Best response to everolimus	Best response to Sunitinib	Best response to platinum	Best response to alkylating agent (temozolomide or dacarbazine)	Peptide Receptor Radionuclide Therapy (PRRT)	Enrollment on clinical trial based on IMPACT	TIme to first recurrence (months)	First Recurrence Resectable for NED	A yes/no indicator that asks whether the patient started adjuvant postoperative radiotherapy.	Has the patient received adjuvant systemic therapy?	What is the number of prior systemic therapies (Inclusion of endocrine, cytotoxic, biologic therapies)?	Has the patient received prior radiotherapy?	Does the patient have brain metastases?	What is the patient's ECOG status?	Legacy DMP patient identifier (DMPnnnn)	12-245 Part A Consented Status	12-245 Part C Consented	Melanoma ulceration indicator	RAF Inhibitor	IMPACT Pre RAFi	KIT Inhibitor	KIT inhibitor type	IMPACT Pre KITi	PSAT IMPACT order	Radiation Therapy.	IMPACT directed SOC Treatment	Text term to signify postoperative adjuvant cancer therapies which use drugs to act upon specific molecules, metabolic pathways or processes involved in carcinogenesis, tumor growth, or tumor spread. [Manually-curated]	Cytotoxic Treatment	Body Mass Index	Protocol Number	Patient Current Age	The text for reporting information about race.	Religion	Sex	The text for reporting information about ethnicity.	Overall patient survival status.	Overall survival in months since initial diagonosis.	Indication on whether this case is a pediatric patient or not	Protocol.	Diabetes Status	Insulin Status	HTN Status	Hl Status	Surgery At MSKCC	Adjuvant Chemotherapy	Treatment best response	Concurrent Treatment	Hormone therapy.	Stage	Text to describe a tumor's histologic subtype or mixed diagnosis that is different from previously specified options.	Performance status	Extent of the primary cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.	Extent of the regional lymph node involvement for the cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.	Treatment Response	Prior History of Ulcerative Colitis	History of Crohn Disease	Insulin use description	Lynch Syndrome	Stage at Testing	Resection of the primary	Resection at MSKCC yes/no indicator	Cytoreductive Surgery	Time till surgery description	R0 Surgery description	Pre-operative Chemotherapy description	Adjuvant chemotherapy receivec	Treatment for MTS Disease Before MTS Sampling	Type of Treatment Before Sampling	Time to metastasis (months).	Neoadjuvant   Systemic Chemotherapy	Year of rc	Recurrence Status Interval Years	Vital Status Interval Years	Resection of Mets	Time To Death (Months)	A yes/no indicator that asks whether the patient startedneoadjuvant preoperative radiotherapy?	Neoadj Systemic Treatment Before First Surgery	Preop RT before first surgery	Adjuvant therapy after first surgery?	Adjuvant RT after first surgery?	Prior fluoropyrimidine (before sample collected for sequencing)	Prior oxaliplatin (before sample collected for sequencing)	Prior irinotecan (before sample collected for sequencing)	Prior anti-EGFR (before sample collected for sequencing)	Prior anti-VEGF (before sample collected for sequencing)	Prior HAI (before sample collected for sequencing)	Prior IP (before sample collected for sequencing)	Prior RT (of sequenced site)	Multiple Breast Primaries	Multiple Breast Primaries Sequenced	For tumors in paired organs, designates the side on which the cancer originates.	Side Surgery	Recurrence at Diagnosis	Distant recurrence.	Time from Diagnosis to IMPACT in months	ER Metastatic Status	PR Metastatic Status	HER2 Metastatic Status	Known Molecular Classifier	ER Primary Status	PR Primary Status	HER2 Primary Status	Menopasue status at Diagnosis	N Stage	Nuclear Grade	Age at BMI Measurement	Height (metres)	Weight measured in kilograms.	BMI Category	Hypertension diagnosis	Hypercholesterolemia	Statin Used	Metformin Used	NSAID Used	F-Uptime in months.	The year in which the participant quit smoking.	Initial LN Status	Biopsy From Irradiated Site	Platinum Doublet	Presence of sarcomatoid features	Histopathology	Category describing current smoking status and smoking history as self-reported by a patient.	Localized or Metastaic at Diagnosis	Patient received Radiation or Chemotherapy	Interval to Mets	Months to local recurrence.	12-245 consent date.	The patient's survival status.	The patient's 12-245 treatment end date.	The patient's 12-245 off study date.	The basic comments at enrollment for 12-245.	Family history of cancer.	Head VS Body/Tail Primary Pancreas	Time to diagnosis with advanced disease	Sample procurred pre chemotherapy	Height in centimeters.	CA-125	Lymph Nodes	Yes or No value if Hysterectomy was performed at MSK	Other History	Risk group.	Extent of the distant metastasis for the cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.	Lvi	Chemotherapy response	Salvage Chemo	Igcccg stage
#STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	NUMBER	NUMBER	STRING	STRING	NUMBER	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	NUMBER	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	NUMBER	NUMBER	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	NUMBER	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING
#0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PATIENT_ID	HCV	HBV	ETOH	NASH	PATHOLOGIC_VASCULAR_INVASION	TIME_TO_UNRESECTABLE_OR_METASTATIC_DISEASE_MONTHS	EXTRAHEPATIC_DISEASE	PRIOR_LOCAL_THERAPY	TYPE_OF_PRIOR_LOCAL_THERAPY	CHILD_PUGH_CLASSIFICATION	SYSTEMIC_TREATMENT	BEST_ORR	AGE	METASTASIS	METASTASIS_BONE	PRIOR_SURGICAL_RESECTION	FIRST_LINE_THERAPY	OS_MONTHS_ADVANCED_DISEASE	OS_MONTHS_DMT	COHORT	DETAILED_PRIMARY_SITE	DFS_MONTHS	SMOKING_HISTORY	SMOKING_PACK_YEARS	TOBACCO_TYPE	ALCOHOL_HISTORY_DOCUMENTED	ALCOHOL_CONSUMPTION_FREQUENCY	INITIAL_TREATMENT	PRIOR_TX_TO_IMPACT_SAMPLE	HPV_STATUS	DFS_STATUS	DISEASE_EXTENT	VITAL_STATUS	WHO_CLASS	HISTOLOGY	IMMUNOSUPPRESSION	CLINICAL_TRIAL	AGENT	COMMENTS	SEX_DMT	OS_STATUS_DMT	HISTOLOGICAL_DIAGNOSIS	METASTASIS_LIVER	METASTASIS_LUNG	METASTASIS_PERITONEUM	TIME_TO_RECURRENCE_MONTHS	PED_AGE	PED_SEX	PEDIATRIC_SAMPLE	TREATMENT	PRIMARY_TUMOR_LOCALIZATION_TYPE	PRIMARY_HISTOLOGY	INITIAL_STAGE	STAGING_SYSTEM	RECURRENCE	ADJUVANT_TX	NUM_PRIOR_THERAPIES	PRIMARY_RADIATION_THERAPY	BRAIN_METS	ECOG_SCORE	RELAPSE	VASCULAR_INVASION_INDICATOR	TURIN	RAI	RAI_UPTAKE	TUMOR_SITE	PRIOR_THYROID_CANCER	RADIATION_HISTORY	FAMILY_HISTORY_CANCER_TYPE	FAMILY_HISTORY_OF_THYROID_CANCER	YEAR_OF_DIAGNOSIS	PATH_CANCER_MAX_DIM_CM	ANAPLASTIC_PERCENTAGE	KI_67	PAX8	PATH_T_STAGE	PATH_N_STAGE	M_STAGE	PATH_MARGIN	LYMPH_NODE_EXAMINED_COUNT	LARGEST_SIZE	EXTRANODAL_INVOLVEMENT	CHEMO_DETAILS	IMPACT_PRE_TKI	TARGET_THERAPY	RESPONSE_TO_TARGET_THERAPY	IMMUNE_TREATMENT	CHEMOTHERAPY	NEUROENDOCRINE_CARCINOMA	MSK_VISITS	TREATMENT_AT_MSK	TREATED_OR_UNTREATED_AT_TIME_OF_INITIAL_VISIT	BLOOD_COLLECTION	MSK_DEPT	SMOKER	COLONOSCOPY	EGD	PET_SCAN	CT_CAP	BRONCHOSCOPY	AGE_AT_INITIAL_PATHOLOGIC_DIAGNOSIS	ECOG_STATUS	PARANEOPLASTIC_SYNDROME	SURGERY	SURGERY_PROCEDURE	BEST_RESPONSE_TO_EVEROLIMUS	BEST_RESPONSE_TO_SUNITINIB	BEST_RESPONSE_TO_PLATINUM	BEST_RESPONSE_TO_ALKYLATING_AGENT	PRRT_THERAPY	ENROLLMENT_ON_CLINICAL_TRIAL_BASED_ON_IMPACT	TIME_TO_FIRST_RECURRENCE	FIRST_RECURRENCE_RESECTABLE_FOR_NED	RADIATION_TREATMENT_ADJUVANT	CRDB_ADJ_TXT	CRDB_NOSYSTXT	CRDB_PRIOR_RX	CRDB_BRAINMET	CRDB_ECOG	OTHER_PATIENT_ID	PARTA_CONSENTED_12_245	PARTC_CONSENTED_12_245	PRIMARY_MELANOMA_TUMOR_ULCERATION	RAF_INHIBITOR	IMPACT_PRE_RAFI	KIT_INHIBITOR	KITI_AGENT	IMPACT_PRE_KITI	PSAT_IMPACT_ORDER	RADIATION_THERAPY	IMPACT_DIRECTED_SOC_TX	TARGETED_MOLECULAR_THERAPY	CYTOTOXIC_TREATMENT	BMI	PROTOCOL_NUM	AGE_CURRENT	RACE	RELIGION	SEX	ETHNICITY	OS_STATUS	OS_MONTHS	PED_IND	PROTOCOL	DIABETES_STATUS	INSULIN_STATUS	HTN_STATUS	HL_STATUS	SURGERY_AT_MSKCC	ADJUVANT_CHEMO	TREATMENT_BEST_RESPONSE	CONCURRENT_TREATMENT	TREATMENT_HORMONE_THERAPY	STAGE	HISTOLOGICAL_SUBTYPE	PERFORMANCE_STATUS	CLIN_T_STAGE	CLIN_N_STAGE	TREATMENT_RESPONSE	HISTORY_OF_ULCERATIVE_COLITIS	HISTORY_OF_CROHNS_DISEASE	INSULIN_USE	LYNCH_SYNDROME	STAGE_AT_TESTING	PRIMARY_RESECTION	RESECTION_AT_MSKC	CYTOREDUCTIVE_SURGERY	TIME_TO_SURGERY	R0_SURGERY	PREOP_CT	ADJUVANT_CT	TREATMENT_FOR_MTS_DISEASE_BEFORE_MTS_SAMPLING	TYPE_OF_TREATMENT_BEFORE_SAMPLING	TIME_TO_MET_MONTHS	NEOADJUVANT_SYSTEMIC_CHEMO	YEAR_OF_RC	RECURRENCE_STATUS_INTERVAL_YEARS	VITAL_STATUS_INTERVAL_YEARS	METASTATIC_RESECTION	TIME_TO_DEATH_MONTHS	RADIATION_TREATMENT_NEOADJUVANT	NEOADJ_TX_BEFORE_FIRST_SURGERY	PREOP_RT_BEFORE_FIRST_SURGERY	ADJ_TX_AFTER_FIRST_SURGERY	ADJ_RT_AFTER_FIRST_SURGERY	PRIOR_FLUOROPYRIMIDINE	PRIOR_OXALIPLATIN	PRIOR_IRINOTECAN	PRIOR_ANTI_EGFR	PRIOR_ANTI_VEGF	PRIOR_HAI	PRIOR_IP	PRIOR_RT_OF_SEQUENCED_SITE	MULTIPLE_BREAST_PRIMARIES	MULTIPLE_BREAST_PRIMARIES_SEQUENCE	LATERALITY	SIDE_SURGERY	RECURRENCE_AT_DIAGNOSIS	DISTANT_RECURRENCE	DX_TO_IMPACT_EXTENT_MONTHS	ER_STATUS_METASTASIS	PR_STATUS_METASTASIS	HER2_STATUS_METASTASIS	KNOWN_MOLECULAR_CLASSIFIER	ER_STATUS_PRIMARY	PR_STATUS_PRIMARY	HER2_STATUS_PRIMARY	MENOPAUSE_STATUS_AT_DIAGNOSIS	N_STAGE	NUCLEAR_GRADE	AGE_AT_BMI_MEASUREMENT	HEIGHT_M	WEIGHT	BMI_CATEGORY	HYPERTENSION_DIAGNOSIS	HYPERCHOLESTEROLEMIA	STATIN_USE	METFORMIN_USE	NSAID_USE	FUPTIME_MONTHS	SMOKING_YEAR_STOPPED	INITIAL_LN_STATUS	BIOPSY_FROM_IRRADIATED_SITE	PLATINUM_DOUBLET	SARCOMATOID_FEATURES	HISTOPATHOLOGY	TOBACCO_SMOKING_HISTORY_INDICATOR	LOCALIZED_VS_METS_AT_DX	RADIATION_OR_CHEMOTHERAPY	INTERVAL_TO_METS	MONTHS_TO_LOCAL_RECURRENCE	CRDB_CONSENT_DATE_DAYS	CRDB_SURVIVAL_STATUS	CRDB_TREATMENT_END_DAYS	CRDB_OFF_STUDY_DAYS	CRDB_BASIC_COMMENTS	FAMILY_HISTORY_OF_CANCER	HEAD_VS_BODY_TAIL_PRIMARY_PANCREAS	TIME_TO_DIAGNOSIS_WITH_ADVANCED_DISEASE	SAMPLE_PRE_CHEMO	HEIGHT	CA_125	LYMPH_NODES	HYSTERECTOMY_AT_MSK	HISTORY_OTHER	RISK_GROUP	CLIN_M_STAGE	LVI	CHEMOTHERAPY_RESPONSE	SALVAGE_CHEMO	IGCCCG_STAGE
P-0003533													20						6.3			14.5									Recurred/Progressed		AWD																																						2014					Tx												Yes																											NO	1	NO	NO	1	N/A		NO														22	White	CATHOLIC/ROMAN	Male	Non-Spanish; non-Hispanic	DECEASED	25.216	No															N1																																																														6												7363	Dead	7981	NA	NA										poor	M0		Resistant	No	
